Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
Shô Miyamoto, Takeshi Arashiro, Yu Adachi, Saya Moriyama, Hitomi Kinoshita, Takayuki Kanno, Shinji Saito, Harutaka Katano, Shun Iida, Akira Ainai, Ryutaro Kotaki, Souichi Yamada, Yudai Kuroda, Tsukasa Yamamoto, Keita Ishijima, Eun‐Sil Park, Yusuke Inoue, Yoshihiro Kaku, Minoru Tobiume, Naoko Iwata‐Yoshikawa, Nozomi Shiwa-Sudo, Kenzo Tokunaga, Seiya Ozono, Takuya Hemmi, Akira Ueno, Noriko Kishida, Shinji Watanabe, Kiyoko Nojima, Yohei Seki, Takuo Mizukami, Hideki Hasegawa, Hideki Ebihara, Ken Maeda, Shuetsu Fukushi, Yoshimasa Takahashi, Tadaki Suzuki
Topics & Concepts
NeutralizationPotencyVirologyVaccinationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Interval (graph theory)2019-20 coronavirus outbreakMedicineMicrobiologyBiologyOutbreakInfectious disease (medical specialty)MathematicsVirusIn vitroGeneticsDiseaseCombinatoricsPathologySARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesCOVID-19 Clinical Research Studies